Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sha Jin

Showing results (141-150 of 148) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 148 results.
Molecular Cancer Therapeutics|September 15, 2011
The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivoJun Chen, Sha Jin, Vivek Abraham, et al.
Leukemia|December 13, 2019
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignanciesDarren C Phillips, Sha Jin, Gareth P Gregory, et al.
Chemical Biology & Drug Design|July 17, 2007
Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategiesJeffrey R Huth, Chang Park, Andrew M Petros, et al.
Journal of Medicinal Chemistry|May 2, 2015
Correction to Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and SelectivityMilan Bruncko, Le Wang, George S Sheppard, et al.
Journal of Medicinal Chemistry|February 14, 2015
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivityMilan Bruncko, Le Wang, George S Sheppard, et al.
Science Translational Medicine|March 20, 2015
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D Leverson, Darren C Phillips, Michael J Mitten, et al.
ACS Medicinal Chemistry Letters|October 15, 2014
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo ActivityZhi-Fu Tao, Lisa Hasvold, Le Wang, et al.
Nature Medicine|January 8, 2013
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J Souers, Joel D Leverson, Erwin R Boghaert, et al.
Pageof 15

Showing results (141-150 of 148) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 148 results.
Molecular Cancer Therapeutics|September 15, 2011
The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivoJun Chen, Sha Jin, Vivek Abraham, et al.
Leukemia|December 13, 2019
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignanciesDarren C Phillips, Sha Jin, Gareth P Gregory, et al.
Chemical Biology & Drug Design|July 17, 2007
Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategiesJeffrey R Huth, Chang Park, Andrew M Petros, et al.
Journal of Medicinal Chemistry|May 2, 2015
Correction to Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and SelectivityMilan Bruncko, Le Wang, George S Sheppard, et al.
Journal of Medicinal Chemistry|February 14, 2015
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivityMilan Bruncko, Le Wang, George S Sheppard, et al.
Science Translational Medicine|March 20, 2015
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D Leverson, Darren C Phillips, Michael J Mitten, et al.
ACS Medicinal Chemistry Letters|October 15, 2014
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo ActivityZhi-Fu Tao, Lisa Hasvold, Le Wang, et al.
Nature Medicine|January 8, 2013
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J Souers, Joel D Leverson, Erwin R Boghaert, et al.
Pageof 15